Stoke Therapeutics (STOK) Projected to Release Earnings on Thursday

Stoke Therapeutics (NASDAQ:STOK) is expected to release its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect Stoke Therapeutics to post earnings of ($0.9291) per share and revenue of $8.21 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:30 PM ET.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Monday, August 3rd. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.13). The firm had revenue of $9.32 million for the quarter, compared to analysts’ expectations of $4.89 million. On average, analysts expect Stoke Therapeutics to post ($3.52) EPS for the current fiscal year and ($3.44) EPS for the next fiscal year.

Stoke Therapeutics Stock Up 2.6%

Shares of Stoke Therapeutics stock opened at $26.13 on Wednesday. Stoke Therapeutics has a one year low of $20.32 and a one year high of $40.22. The stock’s fifty day moving average is $27.78 and its 200 day moving average is $30.97.

Wall Street Analysts Forecast Growth

STOK has been the subject of several recent research reports. Guggenheim reissued a “buy” rating and set a $60.00 price target on shares of Stoke Therapeutics in a report on Tuesday, August 4th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Stoke Therapeutics in a research note on Thursday, September 10th. Canaccord Genuity Group lowered their price objective on Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating on the stock in a research report on Tuesday, August 4th. Wedbush boosted their price objective on Stoke Therapeutics from $38.00 to $40.00 and gave the company an “outperform” rating in a research note on Tuesday, August 4th. Finally, Chardan Capital reissued a “buy” rating and issued a $35.00 target price on shares of Stoke Therapeutics in a report on Tuesday, August 4th. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $44.25.

Insider Buying and Selling at Stoke Therapeutics

In related news, General Counsel Jonathan Allan sold 2,861 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $32.03, for a total transaction of $91,637.83. Following the completion of the sale, the general counsel owned 21,225 shares in the company, valued at approximately $679,836.75. This trade represents a 11.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Edward Kaye sold 12,567 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $32.03, for a total value of $402,521.01. Following the sale, the director owned 124,557 shares of the company’s stock, valued at $3,989,560.71. This represents a 9.16% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 34,594 shares of company stock valued at $1,069,305 over the last ninety days. 9.60% of the stock is currently owned by company insiders.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc is a clinical-stage biotechnology company focused on developing genetic medicines for severe diseases caused by insufficient protein production. The company uses its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform to design antisense oligonucleotides that can increase the expression of specific genes and potentially address the underlying causes of genetic disorders.

Stoke’s leading product candidate is STK-001, an investigational antisense oligonucleotide being developed for the treatment of Dravet syndrome, a severe genetic epilepsy most commonly associated with mutations in the SCN1A gene.